Mochida Pharmaceutical Co., Ltd. (TYO:4534)

Market Cap	105.29B
Revenue (ttm)	105.16B
Net Income (ttm)	5.69B
Shares Out	35.45M
EPS (ttm)	160.36
PE Ratio	18.52
Forward PE	n/a
Dividend	80.00 (2.66%)
Ex-Dividend Date	Mar 28, 2025

Volume	20,000
Average Volume	20,445
Open	2,956.00
Previous Close	2,970.00
Day's Range	2,929.00 - 2,961.00
52-Week Range	2,836.00 - 3,625.00
Beta	0.00
RSI	46.49
Earnings Date	Aug 1, 2025

About Mochida Pharmaceutical

Mochida Pharmaceutical Co., Ltd. manufactures and sells pharmaceuticals and healthcare products in Japan. The company offers pharmaceuticals products for the treatment of cardiovascular, obstetrics, gynecology, dermatology, psychiatry, and gastroenterology. It offers Lialda for the treatment of ulcerative colitis; Goofice and Movicol for the treatment of chronic constipation; Lexapro, an antidepressant drug; Epadel drug for hyperlipidemia and arteriosclerosis obliterans; Urece for the treatment of gout and hyperuricemia; and Treprost for the tr...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1913
• Employees: 1,522
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4534

Financial Performance

In 2024, Mochida Pharmaceutical's revenue was 105.16 billion, an increase of 2.21% compared to the previous year's 102.89 billion. Earnings were 5.69 billion, an increase of 25.03%.